Volume | 96,887 |
|
|||||
News | - | ||||||
Day High | 18.45 | Low High |
|||||
Day Low | 17.88 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Indivior PLC | INDV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
18.43 | 17.88 | 18.45 | 17.95 | 17.93 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,564 | 96,887 | US$ 18.26 | US$ 1,769,349 | - | 14.3809 - 26.50 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:00 | 3,172 | US$ 17.95 | USD |
Indivior PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.97B | 135.27M | - | 1.09B | 2M | 0.01 | 982.43 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Indivior News
Date | Time | Source | News Article |
---|---|---|---|
4/25/2024 | 01:00 | PR Newswire (US) | Indivior Announces Q1 2024 Financial Results |
3/11/2024 | 13:43 | PR Newswire (US) | Indivior Announces Publication Demonstrating that OPVEE®.. |
2/29/2024 | 01:02 | PR Newswire (US) | Court Provides Final Approval of Settlement with Direct.. |
2/22/2024 | 01:00 | PR Newswire (US) | Indivior Announces Q4 / FY 2023 Financial Results |
11/09/2023 | 01:05 | PR Newswire (US) | Indivior Announces Q3 2023 Financial Results |
10/11/2023 | 15:20 | PR Newswire (US) | Indivior Enters an Exclusive Licensing Agreement with Alar.. |
9/26/2023 | 13:30 | PR Newswire (US) | Indivior Publishes Real World Data Showing SUBLOCADE® May.. |
8/21/2023 | 01:02 | PR Newswire (US) | Indivior Reaches Agreement with End Payor Class to Resolve.. |
7/27/2023 | 01:00 | PR Newswire (US) | Indivior Announces Q2/H1 2023 Financial Results |
6/14/2023 | 12:53 | PR Newswire (US) | Indivior Announces Four Abstracts Accepted for Presentation.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INDV Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 17.28 | 18.45 | 17.23 | 17.70 | 150,822 | 0.67 | 3.88% |
1 Month | 21.42 | 21.87 | 17.12 | 18.77 | 125,003 | -3.47 | -16.20% |
3 Months | 17.82 | 23.22 | 16.44 | 20.18 | 143,610 | 0.13 | 0.73% |
6 Months | 20.19 | 23.22 | 14.3809 | 19.14 | 93,788 | -2.24 | -11.09% |
1 Year | 26.50 | 26.50 | 14.3809 | 19.47 | 57,810 | -8.55 | -32.26% |
3 Years | 26.50 | 26.50 | 14.3809 | 19.47 | 57,810 | -8.55 | -32.26% |
5 Years | 26.50 | 26.50 | 14.3809 | 19.47 | 57,810 | -8.55 | -32.26% |
Indivior Description
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. |